Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948)

• Chandrajit P. Raut ,

  Contributed equally to this work with: Chandrajit P. Raut, Yves Boucher, Dan G. Duda

  * E-mail: craut@partners.org

  Affiliations Department of Surgery, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Yves Boucher ,

  Contributed equally to this work with: Chandrajit P. Raut, Yves Boucher, Dan G. Duda

  Affiliations Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Dan G. Duda ,

  Contributed equally to this work with: Chandrajit P. Raut, Yves Boucher, Dan G. Duda

  Affiliations Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Jeffrey A. Morgan,

  Affiliations Department of Medical Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Richard Quek,

  Current address: National Cancer Centre Singapore, Singapore, Singapore

  Affiliations Department of Medical Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Marek Ancukiewicz,

  Affiliations Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Johanna Lahdenranta,

  Affiliations Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• J. Paul Eder,

  Current address: Since the study: AstraZeneca PLC, Boston, Massachusetts, United States of America

  Affiliations Department of Medical Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• George D. Demetri ,

  ¶These authors also contributed equally to this work.

  Affiliations Department of Medical Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Rakesh K. Jain

  ¶These authors also contributed equally to this work.

  Affiliations Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯